Clozapine (Clozaril)

Contents

Clinical Information

 

HALF-LIFE: 5-16 hours

STARTING DOSE: 12.5mg-25mg

TARGET DOSING RANGE: 12.5mg-450mg PO BID

BEST TIME TO DOSE: Evening (but BID dosing required until tolerated)

HOW TO DOSE:

>> Initial 12.5mg PO Once or Twice Daily
>> Increase dose by 25mg-50mg per day to target dose of 300mg-450mg/day over 2-3 weeks
>> If dosing >450mg/day then increase gradually by 50mg weekly
>> Maximum dose is 900mg/day in 2-3 divided doses
>> May take 1-6 months for response
>> If dosing interrupted for >48 hours then restart titration

PREGNANCY: AVOID (if possible)

BREASTFEEDING: AVOID (if possible)

Side Effects

  • Constipation, dry mouth, blurry vision, tachycardia, orthostatic hypotension, urinary retention, agranulocytosis occurs in 0.5-2% of patients (Greatest risk within first 6 months), seizures (rare but may occur at high doses), small risk of myocarditis, sedation, sialorrhea (drooling, increased saliva production), weight gain, increased cardio-metabolic risk (↑triglycerides, insulin resistance)

Drug Interactions

  • Avoid using with benzodiazepines if possible
  • Avoid using with bone marrow suppressing agents (e.g., carbamazepine)

FDA Indications

  1. Treatment-resistant schizophrenia (after 2 failed trials of antipsychotics)
  2. Recurrent suicidal behavior in schizophrenia or schizoaffective disorders

Off Label Uses: For aggression, violence, and treatment resistant bipolar disorder; May reduce severity of tardive dyskinesia (controversial)

Mechanism(s) of Action

Clozapine is a weak dopamine 2 receptor antagonist. Clozapine also has actions at numerous other receptors including D1 receptors, serotonin 5HT2, histaminic receptors, and alpha adrenergic receptors. Interestingly, Clozapine’s antidopaminergic properties are more prominent in the cortical and limbic areas compared to the basal ganglia.

 

Absolute Neutrophil Monitoring (ANC) Schedule

References

  1. Cooper, J. R., Bloom, F. E., & Roth, R. H. (2003). The biochemical basis of neuropharmacology (8th ed.). New York, NY, US: Oxford University Press.
  2. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Introduction to neuropsychopharmacology. Oxford: Oxford University Press.
  3. Puzantian, T., & Carlat, D. J. (2016). Medication fact book: for psychiatric practice. Newburyport, MA: Carlat Publishing, LLC.
  4. J. Ferrando, J. L. Levenson, & J. A. Owen (Eds.), Clinical manual of psychopharmacology in the medically ill(pp. 3-38). Arlington, VA, US: American Psychiatric Publishing, Inc.
  5. Schatzberg, A. F., & DeBattista, C. (2015). Manual of clinical psychopharmacology. Washington, DC: American Psychiatric Publishing.
  6. Schatzberg, A. F., & Nemeroff, C. B. (2017). The American Psychiatric Association Publishing textbook of psychopharmacology. Arlington, VA: American Psychiatric Association Publishing.
  7. Stahl, S. M. (2014). Stahl’s essential psychopharmacology: Prescriber’s guide (5th ed.). New York, NY, US: Cambridge University Press.
  8. Stahl, S. M. (2013). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). New York, NY, US: Cambridge University Press.
  9. Whalen, K., Finkel, R., & Panavelil, T. A. (2015). Lippincotts illustrated reviews: pharmacology. Philadelphia, PA: Wolters Kluwer.